Olfactory receptor in the human bladder may prove beneficial for bladder cancer treatment and diagnosis, according to a new study.
Using cell culture studies, the team headed by Prof. Dr. Dr. Dr. Habil. Hanns Hatt and Dr. Lea Weber demonstrated that the receptor occurs more frequently in bladder cancer tissue than in healthy bladder tissue. Accordingly, significant higher amounts of the receptor could be found in the urine samples of patients.
Bladder Cancer
Bladder cancer occurs due to abnormal cell growth in the urinary bladder. The most common kind usually is urothelial cancer or transitional cell carcinoma.
Advertisement
‘Olfactory receptor can be useful in bladder cancer treatment. The olfactory receptor (OR10H1) in bladder tissue responds to sandalwood scents. Application of Sandranol which is the main component of natural sandalwood oil, the bladder cancer cells altered its shape and became rounder, thereby inhibited tumor growth.’
Tweet it Now
The team from the Department for Cell physiology at Ruhr-Universität Bochum, together with colleagues from the Augusta Hospital in Bochum and the University Hospital in Düsseldorf describes the results in the journal Frontiers in Physiology. The researchers, moreover, explain why the olfactory receptor might be a suitable therapeutic target for cancerous and other diseases of the urinary bladder.
Sandalwood aroma inhibits tumour growth
The olfactory receptor in bladder tissue is named OR10H1. The researchers from Bochum have demonstrated that it responds to sandalwood scents, for example, Sandranol. In collaboration with Prof Dr. Wolfgang Schulz from the University Hospital in Düsseldorf, they analyzed the behavior of cultivated cancer cells when OR10H1 is activated by Sandranol. Hatt and Weber, moreover, identified the signaling pathway that is switched on in the cell when the odorant binds with its receptor.
![New Bladder Cancer Model Could Pave the Way for Better Treatments]( "New Bladder Cancer Model Could Pave the Way for Better Treatments")
New bladder cancer model developed by researchers helps determine which patients may respond to checkpoint inhibitors, a class of immunotherapy drugs that remove the brakes that can keep the immune system from attacking cancer cells.
After application of Sandranol, as well as of Santanol, i.e., the main component of natural sandalwood oil, the bladder cancer cells altered their shape; they became rounder.
Furthermore, cell division occurred less frequently, and cell motility was poorer. "In our cell culture studies, we successfully inhibited tumor growth using sandalwood scent," says Hanns Hatt. This effect was amplified by the fact that receptor activation leads to the release of so-called interleukins as well as ATP, the molecular currency of energy transfer, thus switching on the immune system's natural killer cells in the tissue.
Detectable in urine
The team also analyzed if the higher amount of receptors in bladder cancer tissue can be detected in urine. There, the researchers identified RNA transcripts of the receptors; they occurred in urine samples taken from bladder cancer patients in higher amounts than in healthy humans. "Consequently, OR10H1 might perhaps be used as a biomarker for the diagnosis of bladder cancer with urine samples," concludes Director Dr. Burkhard Ubrig from the Urology Clinic at the Augusta Hospital in Bochum.
Related study with breast cancer cells
In a related study, published in Frontiers in Oncology, the cell physiologists from the Ruhr-Universität Bochum demonstrated that the OR2B6 olfactory receptor occurs exclusively in breast cancer tissue. It does not occur in healthy tissue; outside the nose, it can only be found in small amounts in lung and pancreatic cancer cells. Therefore, the OR2B6 olfactory receptor may be potentially suited as a specific biomarker for breast cancer diagnosis, according to the authors of the study.
"Both studies have confirmed previous research findings made in our lab, namely that olfactory receptors occur outside the nose in both healthy and diseased cells of the body and that particularly high amounts of such receptors can be found in tumor cells," says Hanns Hatt. "In future, they will play an important role not only in the diagnosis of diseases but, first and foremost, they will provide novel approaches in tumor therapy."
Source: Eurekalert
The olfactory receptor in bladder tissue is named OR10H1. The researchers from Bochum have demonstrated that it responds to sandalwood scents, for example, Sandranol. In collaboration with Prof Dr. Wolfgang Schulz from the University Hospital in Düsseldorf, they analyzed the behavior of cultivated cancer cells when OR10H1 is activated by Sandranol. Hatt and Weber, moreover, identified the signaling pathway that is switched on in the cell when the odorant binds with its receptor.
New Bladder Cancer Model Could Pave the Way for Better Treatments
New bladder cancer model developed by researchers helps determine which patients may respond to checkpoint inhibitors, a class of immunotherapy drugs that remove the brakes that can keep the immune system from attacking cancer cells.
Advertisement
After application of Sandranol, as well as of Santanol, i.e., the main component of natural sandalwood oil, the bladder cancer cells altered their shape; they became rounder.
Furthermore, cell division occurred less frequently, and cell motility was poorer. "In our cell culture studies, we successfully inhibited tumor growth using sandalwood scent," says Hanns Hatt. This effect was amplified by the fact that receptor activation leads to the release of so-called interleukins as well as ATP, the molecular currency of energy transfer, thus switching on the immune system's natural killer cells in the tissue.
Detectable in urine
The team also analyzed if the higher amount of receptors in bladder cancer tissue can be detected in urine. There, the researchers identified RNA transcripts of the receptors; they occurred in urine samples taken from bladder cancer patients in higher amounts than in healthy humans. "Consequently, OR10H1 might perhaps be used as a biomarker for the diagnosis of bladder cancer with urine samples," concludes Director Dr. Burkhard Ubrig from the Urology Clinic at the Augusta Hospital in Bochum.
Related study with breast cancer cells
In a related study, published in Frontiers in Oncology, the cell physiologists from the Ruhr-Universität Bochum demonstrated that the OR2B6 olfactory receptor occurs exclusively in breast cancer tissue. It does not occur in healthy tissue; outside the nose, it can only be found in small amounts in lung and pancreatic cancer cells. Therefore, the OR2B6 olfactory receptor may be potentially suited as a specific biomarker for breast cancer diagnosis, according to the authors of the study.
"Both studies have confirmed previous research findings made in our lab, namely that olfactory receptors occur outside the nose in both healthy and diseased cells of the body and that particularly high amounts of such receptors can be found in tumor cells," says Hanns Hatt. "In future, they will play an important role not only in the diagnosis of diseases but, first and foremost, they will provide novel approaches in tumor therapy."
Source: Eurekalert
New Strategy for Treating Bladder Cancers
Arginine-degrading-enzyme therapy is beneficial for the treatment of cancers lacking the enzyme needed for arginine synthesis (argininosuccinate synthetase 1).
Advertisement
 Urine Test Helps Detect Bladder Cancer RecurrenceThe presence of Telomerase reverse transcriptase in the urine helps predict recurrence of bladder cancer in more than 80% of patients. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
Colorectal cancer can be lowered by up to 7% by increasing dietary consumption of folate rich foods like spinach, broccoli or taking folate supplements.
The effects and mechanisms of microRNA-451a (miR-451a), which hinders the progression of gemcitabine-resistant biliary tract cancers, are under study.
The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.
A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.
Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.